Survival curves of patients with NPM1-mutated/FLT3-ITD⁻ AML (MLD⁺ vs MLD⁻) from GIMEMA LAM99P and GIMEMA/EORTC AML12 trials. (A) No significant differences in OS are observed between NPM1-mutated/FLT3-ITD⁻ AML with (red line) and without (blue line) MLD (P = .994). (B) No significant differences in EFS are observed between NPM1-mutated/FLT3-ITD⁻ AML with (red line) and without (blue line) MLD (P = .877). (C) No significant differences in OS are observed between normal karyotype NPM1-mutated/FLT3-ITD⁻ AML with (red line) and without (blue line) MLD (P = .768). (D) No significant differences in EFS are observed between normal karyotype NPM1-mutated/FLT3-ITD⁻ AML with (red line) and without (blue line) MLD (P = .888).